Piramal Pharma Reports on Sustainability and ESG Performance for FY2025-26, Highlighting Resource Efficiency and Labor Practices

Piramal Pharma Reports on Sustainability and ESG Performance for FY2025-26, Highlighting Resource Efficiency and Labor Practices​

Piramal Pharma Limited (PPL), a major player in pharmaceutical manufacturing, has provided its Business Responsibility and Sustainability Report (BRSR) covering the financial year 2025–2026. The report details the company's operational scale, commitment to environmental stewardship, and social governance across its global operations, emphasizing resource management and employee well-being.

The company is a diversified entity with significant international reach. Its main business activity involves the manufacturing of pharmaceuticals, medicinal, chemical, and botanical products, contributing 100% to its turnover. PPL serves markets both nationally and internationally, exporting 72.78% of its total turnover. The firm maintains a strong operational footprint, operating 9 plants across India and 7 international sites.

Operational Scale and Governance Structure​

Piramal Pharma Ltd., incorporated in 2020, reported paid-up capital of ₹1,329.25 Crores. The company has built an extensive portfolio of subsidiaries globally. These entities include Piramal Critical Care Deutschland GmbH (a subsidiary), Piramal Healthcare UK Limited, and numerous other international operations such as Piramal Pharma Inc. and PPL Pharma Solutions Riverview LLC.

The business also includes investments in associated companies, with Abbvie Therapeutics India Private Limited representing a 49% shareholding, while Yapan Bio Private Limited holds a 33.33% stake. The company's management structure is overseen by a Sustainability and Risk Management Committee, which is chaired by the Company’s Chairperson and focuses on ESG strategy alignment.

Environmental Stewardship and Resource Management​

A core focus of the BRSR report is environmental sustainability. PPL reports significant efforts toward resource conservation, with zero incinerable hazardous waste being sent to landfill in India. The company has implemented a strong decarbonization strategy aligned with Science-Based Targets initiative (SBTi).

Regarding energy usage, total energy consumed stood at 14,20,663 GJ for FY2025–26. A notable achievement is the adoption of renewable energy; certain plants have incorporated significant sustainable practices. For instance, the Ennore plant sourced approximately 60% of its total energy requirement through solar and wind power, while the Dahej plant operationalized a hybrid power system along with a 137 kW solar plant.

Water management is also highly monitored. The company successfully recycled and reused 1,91,887 kL of water during FY2025–26 across various sites (including Rabale, Dahej, Ennore, Pithampur, and Digwal), significantly reducing freshwater intake. PPL's operations adhere to relevant environmental regulations regarding air emissions, with all monitored pollutant levels remaining below limits.

The commitment to circularity includes managing waste generation responsibly. Total waste generated stood at 29,043.97 MT for the year, of which 18,611.63 MT was recycled. The company maintains a commitment across its sites based on the five R's (reduce, reuse, recycle, recover, and rethink) to manage waste generation.

Social Impact and Labor Practices​

The report details PPL’s commitment to employee well-being and responsible labor practices. Total employees stood at 6,774, with a focus on training and development across all workforce categories.

Key metrics related to employment include:

• Employee Retention: The retention rate for female permanent employees was reported at 90%, while the return to work rate for female employees after parental leave was 97.3%.
• Labor Standards: PPL reported zero instances of child labor or forced/involuntary labor among all surveyed categories (employees and workers) for FY2025–26.
• Wages: The gross wages paid to females represented 20.82% of total wages in FY2025–26, up from 13.88% in the previous year.

The company maintains a zero-tolerance approach to workplace misconduct. For instance, grievance data showed that out of 5 complaints filed during FY2025–26 regarding Sexual Harassment, 2 were upheld.

Business Integrity and Supply Chain Management​

PPL's business integrity is anchored by a comprehensive Anti-Corruption and Anti-Bribery (ACAB) Policy, which applies across all global units and covers stakeholders including suppliers and partners. The company reported zero instances of disciplinary action taken against Directors, Key Managerial Personnel, Employees, or Workers for bribery or corruption during FY2025 and FY2026.

Regarding the supply chain, PPL maintains a system to assess value chain partners on ESG criteria. Of all relevant suppliers, 14.42% were assessed for environmental and social impacts. The company's procurement practices also ensure that inputs from directly sourced MSMEs/small producers constituted 25% of total purchases in FY2025–26.

Workforce and Safety Metrics Summary​

The report provides detailed metrics on the workforce across both employees and workers:


In conclusion, the BRSR demonstrates PPL's dedication to integrating sustainability goals with core business operations, showing tangible improvements in resource efficiency and maintaining high standards across its complex global supply chain and workforce.

PPLPHARMA Stock Price Movement​

Today, shares of Piramal Pharma Limited rallied, closing at ₹175.30 after surging 4.17% on the day. The stock saw robust trading activity, logging a traded volume of 33.41 million shares within an intraday range defined by a low of ₹168.1 and a high of ₹179.25.